title: Gamma imaging with negatively charge-modified monoclonal antibody: modification with synthetic polymers.
abstract: Antimyosin Fab has been modified to carry highly negatively charged synthetic polymers containing DTPAs (DTPA-PL) as chelating agents, of starting molecular weights 3.3 and 17 kD. The immunoreactivities of the modified antibodies were unaffected by the modification procedure. The isoelectric points (PI) of unmodified antimyosin (AM) Fab (PI range 7-9, Mr = 52kD) were changed to PIs predominantly between 4 and 5 (Mr = 59 kD for DTPA-PL3.3kD-AM-Fab and 67kD for DTPA-PL17kD-AM-Fab). These AM-Fab preparations were tested for specific target localization and visualization in vivo in an experimental canine model of acute myocardial infarction. The charge-modified 111In-labeled AM-Fab preparations showed enhanced target (necrotic myocardium) visualization within 30 min of intravenous infusion and decreased background activity in normal myocardium (mean %ID/g +/- s.e.m., 0.0076 +/- 0.0006, n = 164, and 0.0056 +/- 0.0004, n = 92, for 111In-DTPA-PL3.3kD- and DTPA-PL17kD-AM-Fab respectively) relative to conventional 111In-DTPA-AM-Fab (0.0263 +/- 0.0037, n = 135) (p less than 0.001) or radioiodinated AM-Fab (0.0098 +/- 0.0006, n = 256) (p less than or equal to 0.001). Furthermore, the concentration of negatively charged 111In-labeled antimyosin Fab decreased in non-target organs such as the liver and kidneys. In diagnostic and therapeutic applications, charge-modified macromolecules may improve target localization and reduce non-target organ activity.
authors.affiliation: Division of Nuclear Medicine, Massachusetts General Hospital, Boston.
authors.forename: B A
authors.initials: BA
authors.lastname: Khaw
authors.forename: A
authors.initials: A
authors.lastname: Klibanov
authors.forename: S M
authors.initials: SM
authors.lastname: O'Donnell
authors.forename: T
authors.initials: T
authors.lastname: Saito
authors.forename: N
authors.initials: N
authors.lastname: Nossiff
authors.forename: M A
authors.initials: MA
authors.lastname: Slinkin
authors.forename: J B
authors.initials: JB
authors.lastname: Newell
authors.forename: H W
authors.initials: HW
authors.lastname: Strauss
authors.forename: V P
authors.initials: VP
authors.lastname: Torchilin
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics*; D004285:Dogs; D007140:Immunoglobulin Fab Fragments; D007205:Indium Radioisotopes / Q000493:pharmacokinetics*; D007457:Iodine Radioisotopes; D009203:Myocardial Infarction / Q000000981:diagnostic imaging*; D009942:Organometallic Compounds / Q000493:pharmacokinetics*; D004369:Pentetic Acid / Q000493:pharmacokinetics*; D011107:Polylysine / Q000493:pharmacokinetics*; D011877:Radionuclide Imaging; D014018:Tissue Distribution
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D009942:Organometallic Compounds; D011107:Polylysine; C058899:imciromab pentetate; D004369:Pentetic Acid